Phase 1 Study of the Safety and Immunogenicity of VAX2012Q: A Quadrivalent Influenza Vaccine in Healthy Adults Age 18-40 Years

Trial Profile

Phase 1 Study of the Safety and Immunogenicity of VAX2012Q: A Quadrivalent Influenza Vaccine in Healthy Adults Age 18-40 Years

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs VAX 2012Q (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Sponsors VaxInnate
  • Most Recent Events

    • 18 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 09 Sep 2014 Results presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 19 Mar 2014 Results are expected by the end of 2014 according to a VaxInnate Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top